A New Concept for Acne Therapy: A Pilot Study With Zileuton, an Oral 5-Lipoxygenase Inhibitor

Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes

“…We additionally found that CBD also prevented the "pro-acne" LA-T combination from elevating the expression of TNFA ( Figure 3A), a key cytokine in the pathogenesis of acne vulgaris (2,(24)(25)(26)(27)(28)(29)(30). These data suggested that CBD may exert antiinflammatory actions on human sebocytes (as had already been demonstrated for CBD in several other experimental models, such as diabetes, rheumatoid arthritis, etc.)…”

“…We also investigated the effects of CBD on the lipidome of SZ95 sebocytes under in vitro conditions that mimicked "acnelike" circumstances (the latter was achieved by using a key "proacne" inflammatory mediator, AA) (1,2,21,(24)(25)(26). Importantly, CBD almost completely normalized the AA-enhanced "pathological" lipogenesis of SZ95 sebocytes ( Figure 1G).…”

Beyond acne: Current aspects of sebaceous gland biology and function

“…However, the activity of PPAR agonists seems to be complex: PPARγ agonists have been shown to increase sebum production in adults with diabetes and hyperlipidemia [64]. In contrast, PPARα agonists seem to inhibit sebaceous lipogenesis [65] through prevention of the activation of the proinflammatory leukotriene pathway [66]. Moreover, PPAR agonists, especially that for PPARδ, exhibit anti-apoptotic activity on human sebocytes by inducing the activation of PKB/Akt and p44/42, two kinases involved in anti-apoptosis and proliferation, respectively and by suppressing histone-associated DNA fragments [67].…”

The relationship of diet and acne

“…Antinflammatory compounds such as zileuton, which targets certain enzymes of the lipid oxidation pathways, are in clinical studies. 33,34 These pathways involve metabolites of polyunsaturated fatty acids. As in the case of vitamins there are also two fatty acids in our body that cannot be synthesized by human cells: linoleic (18:2, D9,12) and α-linolenic acid (18:2, D9,12,15) (αLA).…”